Drug Discovery Patents

1.          “O²-aryl substituted diazeniumdiolates and use thereof,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, C. Bogdan, W.G. Rice, and X. Ji, Australia Patent 733590 (2001).

2.          “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, C. Bogdan, W.G. Rice, and X. Ji, US Patent 6610660 (2003).

3.          “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, European (Belgium, France, Ireland, Italy, Switzerland, and United Kingdom) Patent 0929538 (2004).

4.          “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Germany Patent 69731758.7-0 (2005).

5.          “O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, US Divisional Patent 6911433 (2005).

6.          “O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, US Divisional Patent 7081524 (2006).

7.          “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Japan Patent 4285775 (2009).

8.          “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Canada Patent 2266908 (2010).

9.          “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Japan Divisional Patent 5015903 (2012).

10.       “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Canada Divisional Patent 2705474 (2013).

11.       “O²-arylated or O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O²-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, European (France, Germany, and United Kingdom) Divisional Patent 1439187 (2013).

12.       “Linked purine pterin HPPK inhibitors useful as antibacterial agents,” G. Shi, G. Shaw, and X. Ji, US Patent 9029344 (2015).

13.       “PARP inhibitor/NO donor dual prodrugs as anticancer agents,” A. Maciag, J. Saavedra, L. Keefer, X. Ji, and V. Kumari, US Patent 9168266 (2015).